1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Vedanta Phase II Data Position It To Chase Seres In C. Difficile Recurrence

 
• By Joseph Haas

Vedanta thinks its live biotherapeutic sourced from clonal cell banking could offer strong prevention against C. difficile infections after antibiotics have cleared an initial infection.

Bacterias 3D rendering
Vedanta thinks its live biotherapeutic can prevent infection recurrence

Chasing Seres Therapeutics, Inc. for the first microbiome product approval, Vedanta Biosciences, Inc. reported on 5 October that its live biotherapeutic product VE303 has succeeded in a Phase II study preventing recurrence of Clostridium difficile infections and is ready to move into Phase III in 2022. On the news of the successful Phase II study, the US Biomedical Advanced Research and Development Authority (BARDA) exercised a contract option to provide $23.8m to fund the Phase III study.

After clinical setbacks in 2017, Seres rebounded in 2020 with positive Phase III data for SER-109 –comprised of highly purified...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Nanobiotix/J&J Early Melanoma Data Show Potential For Future Indication

 
• By Mandy Jackson

Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.

EADV: Leo Makes A Big Leap With Eczema Drug Temtokibart Set For Phase III

 
• By Kevin Grogan

CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

More from R&D

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.

AstraZeneca’s Fasenra RESOLUTE Failure Highlights The Limits Of Biologics In COPD

 
• By Alexandra Shimmings

AstraZeneca’s IL-5 blocker has again missed in COPD, adding to a number of disappointments for biologics in this disease. Complex biology and overlapping inflammatory pathways seem to be at the heart of the problem.